The company's photodynamic therapy drug "Aminolevulinic Acid Hydrochloride" (118mg/vial) (ALA^®) project has been successfully selected the "National New Products Program" and awarded as the "National Strategic Innovative Product". The "National New Products Program" in 2014 focused on cultivating and developing strategic emerging industries, saving energy and reducing emissions, and continuing to increase support for the new high-tech products with independent intellectual property rights.
The award for the " National Strategic Innovative Product" fully reflects this project's strategic value in the national economic development, significant role in guaranteeing and improving people's livelihood and accelerating technological progress of the bio-pharmaceutical industries, and gives credit for this innovative product with a technological breakthrough, independent intellectual property rights and a strong competitive advantage in markets.